Humacyte Inc (HUMA)
$5.39
Market is closed - opens 7 PM, 10 Oct 2024
Performance
- $5.34$5.55$5.39
1.02%
Downside
Day's Volatility :3.87%
Upside
2.88%
- $1.96$9.97$5.39
63.64%
Downside
52 Weeks Volatility :80.34%
Upside
45.94%
Returns
| Period | Humacyte Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -5.21% | 4.7% | 0.0% |
6 Months | 82.57% | 5.9% | 0.0% |
1 Year | 93.38% | 16.3% | 0.0% |
3 Years | 54.17% | 19.6% | -20.8% |
Highlights
Market Capitalization | 689.3M |
Book Value | - $0.24 |
Earnings Per Share (EPS) | -1.27 |
Wall Street Target Price | 12.14 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -43.61% |
Return On Equity TTM | -850.81% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 1.6M |
EBITDA | -99.6M |
Diluted Eps TTM | -1.27 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.21 |
EPS Estimate Next Year | -0.86 |
EPS Estimate Current Quarter | -0.24 |
EPS Estimate Next Quarter | -0.24 |
Analyst Recommendation
Buy
83%Buy
16%Hold
0
0%Sell
Based on 12 Wall street analysts offering stock ratings for Humacyte Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
- Current
- 1M Ago
- 3M Ago
Buy
10
11
11
Hold
2
2
2
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 125.23%
Current $5.39
Target $12.14
Technicals Summary
Sell
Neutral
Buy
Humacyte Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Humacyte Inc | 2.97% | 82.57% | 93.38% | 54.17% | 54.17% |
 Regeneron Pharmaceuticals, Inc. | -12.19% | 6.5% | 20.85% | 84.03% | 245.65% |
 Novo Nordisk A/s | -11.15% | -6.13% | 27.31% | 138.21% | 354.53% |
 Alnylam Pharmaceuticals, Inc. | 7.12% | 73.95% | 61.12% | 32.59% | 252.19% |
 Vertex Pharmaceuticals Incorporated | -2.58% | 13.46% | 29.21% | 155.56% | 172.0% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Humacyte Inc | 1.0 | NA | NA | -1.21 | -8.51 | -0.44 | NA | -0.24 |
Regeneron Pharmaceuticals, Inc. | 26.59 | 26.59 | 1.37 | 45.03 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.73 | 39.73 | 1.79 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Humacyte Inc | Buy | $689.3M | 54.17% | 1.0 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.8B | 245.65% | 26.59 | 32.04% |
Novo Nordisk A/s | Buy | $522.1B | 354.53% | 39.73 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.2B | 252.19% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $118.5B | 172.0% | 32.84 | -4.74% |
Insights on Humacyte Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 31.0K → 10.79M (in $), with an average increase of 99.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -25.10M → -56.66M (in $), with an average decrease of 52.4% per quarter
Institutional Holdings
BlackRock Inc
5.98%Vanguard Group Inc
3.96%State Street Corp
2.40%Geode Capital Management, LLC
1.56%Millennium Management LLC
1.34%Nuveen Asset Management, LLC
1.04%
Company Information
biotechnology company
Organization | Humacyte Inc |
Employees | 183 |
CEO | Dr. Laura E. Niklason M.D., Ph.D. |
Industry | Healthcare |
